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Abstract
Chronic myelomonocytic leukemia (CMML) is a clinically heterogeneous neoplasm in which JAK2 inhibition has
demonstrated reductions in inflammatory cytokines and promising clinical activity. We hypothesize that annotation of
inflammatory cytokines may uncover mutation-independent cytokine subsets associated with novel CMML prognostic
features. A Luminex cytokine profiling assay was utilized to profile cryopreserved peripheral blood plasma from 215 CMML
cases from three academic centers, along with center-specific, age-matched plasma controls. Significant differences were
observed between CMML patients and healthy controls in 23 out of 45 cytokines including increased cytokine levels in IL-8,
IP-10, IL-1RA, TNF-α, IL-6, MCP-1/CCL2, hepatocyte growth factor (HGF), M-CSF, VEGF, IL-4, and IL-2RA. Cytokine
associations were identified with clinical and genetic features, and Euclidian cluster analysis identified three distinct cluster
groups associated with important clinical and genetic features in CMML. CMML patients with decreased IL-10 expression
had a poor overall survival when compared to CMML patients with elevated expression of IL-10 (P= 0.017), even when
adjusted for ASXL1 mutation and other prognostic features. Incorporating IL-10 with the Mayo Molecular Model statistically
improved the prognostic ability of the model. These established cytokines, such as IL-10, as prognostically relevant and
represent the first comprehensive study exploring the clinical implications of the CMML inflammatory state.
Introduction
Chronic myelomonocytic leukemia (CMML) is a hemato-
poietic neoplasm with features of both myelodysplastic
(MDS) and myeloproliferative (MPN) diseases hallmarked
by a peripheral blood monocytosis (≥1 × 109/L) that con-
stitutes greater than 10% of white blood cells [1]. CMML is
often accompanied by cytopenias and/or the presence of
constitutional symptoms such as fatigue, weight loss, night
sweats, symptoms from organomegaly (early satiety or
abdominal pain) [1]. Previous French-American-British
(FAB) classifications separate CMML based on white
blood cell count into MPN-CMML and MDS-CMML [2].
World Health Organization (WHO) classifications separate
CMML based on bone marrow blast count in three prog-
nostically relevant groups [1]. However, these classification
systems do not fully exemplify the clinical heterogeneity
observed in CMML because many clinically relevant
symptoms such as constitutional symptoms, splenomegaly,
and peripheral cytopenias are not captured. Although
recurrently mutated genes in CMML have been rigorously
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annotated, the spectrum of mutations is homogeneous
relative to other adult cancers and also does not reflect the
clinical diversity seen in patients with CMML [3–6].
To address the wide clinical heterogeneity, many inves-
tigators have devised prognostic scoring systems that pre-
dict overall and leukemia-free survival [7–11]. We have
demonstrated that, although valid and reproducible, these
prognostic scores have only modest predictive capacity and
are vulnerable to up-staging via competing models [12].
Numerous studies have also explored the prognostic capa-
city of somatic gene mutations in CMML [3, 13, 14].
Despite several independent studies, only ASXL1 frameshift
or nonsense mutations have demonstrated to be indepen-
dently and reproducibly associated with survival [3, 15, 16].
This has led to at least three new prognostic scoring systems
that incorporate ASXL1 and clinical features [3, 12, 15–18].
Given these efforts, we reason that identifying non-
mutational molecular characteristics may further refine
prognostication in CMML.
We have demonstrated that ruxolitinib, a JAK1/2 inhibitor
FDA approved for treatment of primary myelofibrosis (PMF),
is an effective therapeutic in CMML [19, 20]. Similar to that
seen in MPNs, CMML patients treated with ruxolitinib were
found to have marked reduction in circulating inflammatory
cytokines and improvement in constitutional symptoms and
spleen volume [19, 21, 22]. Previous literature investigating
JAK inhibition in MPNs has demonstrated that inflammatory
cytokines are reduced or normalized after treatment correlating
with symptom improvement [19, 22, 23]. This suggests that
inflammatory cytokines may associate with clinical features
not captured by current models or genetic mutations. How-
ever, the spectrum of cytokine secretion in CMML has not
been previously comprehensively evaluated in the literature.
To understand the non-mutational molecular correlates
driving CMML clinical diversity, we comprehensively profiled
the inflammatory secretome in CMML patients. We hypo-
thesize that annotation of inflammatory cytokines may uncover
cytokine subsets associated with CMML-specific clinical and
genetic features and refine existing prognostic models.
Methods
Patient samples and controls
The study was approved by the Institutional Review Board
(IRB) for each respective institution including Moffitt Cancer
Center (Tampa, Florida), Institute Gustave-Roussy (Paris,
France), and the University of Florence (Florence, Italy). All
patients provided informed written consent for the collection
of peripheral blood and bone marrow samples and required a
confirmed WHO diagnosis of CMML [1]. Age-matched,
center-specific controls (n= 35) were also obtained under
institute-specific IRB-approved protocols. Fifteen single
donor healthy control plasma samples were purchased from
Innovative Research (Innovative Research, Inc., Novi, MI)
with an average age 66 (range 60–80) and a total of nine men
and six women. These 15 samples from Innovative Research,
Inc. were used as comparison for samples from Moffitt
Cancer Center and University of Florence. All healthy control
plasma samples were obtained at an FDA licensed commer-
cial donor center or facility within the United States and each
sample was tested and found negative for Hepatitis B,
Hepatitis C, HIV, and syphilis as well as negative for active
diagnosis of cancer. Twenty single donor healthy control
plasma samples were obtained by the Institute Gustave-
Roussy as comparison for their samples. Pretreatment plasma
was isolated from whole blood and bone marrow samples
obtained from patients at each individual institution (Fig. 1).
Cytokine secretion profiling
Cytokine expression levels were measured, in duplicate,
from plasma samples using a custom 45-plex Luminex-
based inflammatory cytokine screening assay kit and
Luminex 100TM according to the manufacturer’s protocol
(R&D Systems, Minneapolis, MN). Forty-five cytokines
(Supplemental Table 1) were analyzed, which included 19
cytokines previously implicated in the pathogenesis of
myeloid neoplasms [24]. Cytokine measurements for the
CMML patients were normalized to the site-specific healthy
control for each batch and a fold change was calculated for
each cytokine measured for every CMML patient and
healthy control enrolled in the study. Cytokine expression
levels with a fold change above 1 in the CMML patients
were deemed elevated compared to healthy normal controls,
and cytokine expression levels with a fold change less than
1 in the CMML patients were deemed to be decreased
compared to healthy normal controls.
Somatic mutation profiling
Gene mutation testing was achieved via specific, in-house,
targeted next-generation sequencing platform. Both full
gene and hotspot sequencing were generated on the fol-
lowing genes: TET2, ASXL1, SRSF2, CSF3R, KRAS, NRAS
CBL, DNMT3A, SF3B1, EZH2, JAK2, IDH1/2, FLT3,
SETBP1, U2AF1, and ZRSR2. All variants reported were
manually reviewed and validated to be variants of known
significance as previously described [25].
Colony formation assay and gene expression
analysis
Colony formation assays from cryopreserved primary
CMML bone marrow mononuclear cells were conducted in
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Fig. 1 Inflammatory cytokines are heterogeneously expressed in
CMML patients. a Study design. b Significant differences observed in
measured inflammatory cytokines in patients with CMML compared to
healthy aged-matched controls. Y-axis is negative log(P-value). X-axis
is fold change of CMML compared to healthy aged-matched controls. c
Violin plot displaying the variable distribution of cytokine expression
for each cytokine in CMML patients. On the y-axis is the log of the fold
change for CMML patients. On the x-axis is each of the 45 cytokines
evaluated. Cytokines to left of vertical dotted line were statistically
significant when comparing expression in CMML patients to normal
controls (P < 0.05). d Pearson correlation displaying cytokine–cytokine
interaction in 45 cytokines measured in CMML patients. Top figure
displays positive and negative cytokine interactions in normal patients
and bottom section of figure displays cytokine interactions in CMML
patients. Blue notes negative R coefficient correlation while red notes
positive R coefficient correlation. e The difference of correlation
between CMML patients and normal patients. The colored squares
represent all statistically significant interactions. The more blue present
in the square denotes more negative R coefficient correlation between
two cytokines while the more red in the square denotes more positive R
coefficient correlation. Interactions between cytokines that were not
statistically significant are shaded white
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duplicate using Methocult substrate (Stemcell, Vancouver,
Canada) as previously described by our group in the pre-
sence or absence of human recombinant interleukin-10 (IL-
10) or IL-8 (Stemcell) at a concentration of 10 μg/mL [26].
Cryopreserved primary CMML bone marrow mononuclear
cells were thawed from seven CMML patients enrolled in
our study for the assay. Colonies were counted using the
StemVision automated colony-counting instrument and
software (Stemcell). A paired T-test was used to compare
colony output between patient samples. Multiplex gene
expression analysis was performed using Nanostring
nCounter PanCancer Pathway Panel and nSolverTM Ana-
lysis software (NanoString Technologies, Inc., Seattle, WA)
on four CMML patients enrolled in our study.
Statistical methods
Cytokine expression levels were derived using Luminex
software MasterPlex 2010 (MiraiBio Group of Hitachi
Solutions America, Ltd). All analyses involving cytokines
were completed after applying a log-transformation to
reduce the impact of outliers. Principal component analysis
(PCA) was completed with the first two principal compo-
nents (PCs) plots to investigate potential batch effects.
Cytokine expression levels were adjusted for batch effect
(i.e., day the sample was run) using an ANOVA model for
each cytokine (see Supplemental Methods). PCA demon-
strated significant batch effect that was corrected by using an
ANOVA model that considered the timing of experiments
(Supplemental Fig. 1). Comparison of peripheral blood
cytokines in CMML patients to each respective healthy age-
matched and center-matched control was completed using
Wilcoxon rank sum test. Cytokine levels in the peripheral
blood of 20 CMML patients were compared to matched
bone marrow samples using Pearson’s correlation. Log-rank
tests were used to determine if individual cytokines (high/
low) or clusters of cytokines were independently associated
with overall survival (OS). Cox proportional hazards models
were used to incorporate clinical and gene variables into a
multivariate survival model. Model development was com-
pleted by first including any clinical, genetic, or cytokine
variable with P < 0.05 into an initial model, followed by
backward elimination to remove variables with P > 0.05
from the final model. Proportional hazards assumptions were
confirmed with Schoenfeld residual plots. Cluster analysis
was completed on the log-transformed batch-adjusted cyto-
kine data with Gaussian model-based clustering using the R
package mclust [27, 28] and Recursively Partitioned Mixture
Model with R package RPMM [29]. Determination of dif-
ference in OS between the clusters was completed using log-
rank tests. Statistical analysis was completed in collaboration




A total of 215 patients with a diagnosis of CMML and
median age of 74 (range 29–91, 65% males) had diagnostic
pretreatment peripheral blood plasma samples available for
the study. Of the 215 CMML patients with available clinical
and genetic information, 105 (61% of evaluable patients)
patients were classified in the CMML-0 subgroup, 43 (25%
of evaluable patients) patients in the CMML-1, 25 (14% of
evaluable patients) patients in the CMML-2 subgroup by
2016 WHO classification(1), and 42 patients did not have
clinical data available (Table 1). Overall, 122 (68% of
evaluable patients) CMML patients had a hemoglobin level
greater than 10 g/dL (median 11.2, range 5.9–16.7 g/dL), 58
(32% of evaluable patients) patients with hemoglobin less
than 10 g/dL, and 35 patients did not have clinical data.
TET2 was the most common mutation seen in our cohort
with 87 patients (58% of evaluated patients) with mutated
TET2. Our patient demographics and clinical characteristics
are summarized in Table 1 and Supplemental Table 2.
Concordance between bone marrow and peripheral
blood samples
Because our study focused on annotating peripheral blood
cytokine levels, we explored the concordance between
peripheral blood and bone marrow plasma samples in 20
CMML patients with blood and bone marrow obtained
concomitantly. When all data were aggregated across
patients, we found a positive concordance between bone
marrow plasma samples and peripheral blood samples of the
majority of the cytokines evaluated (r= 0.7891, P < 0.0001,
95% CI 0.592–0.8971), suggesting that peripheral blood is a
reasonable representation of the bone marrow cytokine
milieu. However, certain cytokines appeared to be dis-
cordant suggesting enrichment or de-enrichment in the bone
marrow compared to peripheral blood. These discordant
cytokines included Granulocyte-macrophage colony-stimu-
lating factor (GM-CSF) (r=−0.1395), vascular endothelial
growth factor (VEGF) (r=−0.1415), and tumor necrosis
factor-α (TNF-α) (r=−0.1561) (Supplemental Fig. 2).
Cytokine expression in CMML patients compared to
matched controls
We evaluated the peripheral inflammatory secretome of
CMML by annotating 45 chemokine/cytokine levels and
compared these levels to age- and center-matched normal
controls (n= 35) (Fig. 1a, b; Supplemental Table 3). After
data normalization and quality control, significant differ-
ences in 23 of 46 cytokine levels between CMML and
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healthy controls were measured. We observed significantly
downregulated FLT-3 ligand (fold change (FC)= 0.4),
PDGF-AA (FC= 0.3), PDGF-BB (FC= 0.04), PDGF-CC
(FC= 0.5), PDGF-DD (FC= 0.4), EGF (FC= 0.6),
TRAIL/TNFS10 (FC= 0.5), and CCL5/RANTES (FC=
0.1) when comparing CMML patients to healthy age-
matched controls (P ≤ 0.001). IL-8 (FC= 8.3), IP-10 (FC=
1.2), and IL-1RA (FC= 1.5) were found to be significantly
elevated in CMML patients compared to healthy age-
matched controls (P ≤ 0.001) (Fig. 1b, Supplemental
Table 3). Proinflammatory cytokines including TNF-α
(FC= 3, P= 0.011), IL-6 (FC= 2.6, P= 0.0129), MCP-
1/CCL2 (FC= 2.1, P= 0.0114), macrophage colony-
stimulating factor (M-CSF) (FC= 2.6, P= 0.0035), HGF
(FC= 2, P= 0.0061), VEGF (FC= 2.2, P= 0.0223), IL-4
(FC= 2.4, P= 0.0499), and IL-2RA (FC= 1.5, P=
0.0269) were found to be significantly elevated in CMML
patients. We observed significant CMML cytokine/chemo-
kine heterogeneity within our cohort, suggesting that
annotating the secretome may reveal relevant disease sub-
sets. We therefore reasoned that cytokines/chemokines that
were not observed to be statistically up- or downregulated
should be considered in our downstream analysis (Fig. 1c).
Inflammatory cytokine signals are an established feature
of stress-induced hematopoiesis and the secreted inflam-
matory response [30]. We hypothesized that CMML
patients may exhibit distinct cytokine expression patterns
due to underlying somatic mutations. To evaluate this, we
used Pearson’s correlation to determine pairwise correla-
tions between cytokines measured in CMML and normal
age-matched controls, respectively (Fig. 1d, e, Supple-
mental Tables 4–6). Cytokine associations were identified
in CMML patients not seen in normal controls between IL-
1β, IL-6, IL-8, and TNF-α previously identified in the lit-
erature in other proinflammatory diseases such as osteoar-
thritis [31–35]. Only in normal control patients, GM-CSF
was positively correlated with IL-5 (r= 0.577, P= 0.0002)
and CXCL7 (r= 0.432, P= 0.009), but negatively corre-
lated with IL-2RA (r=−0.449, P= 0.006), HGF (r=
−0.341, P= 0.044), and MIF (r=−0.628, P < 0.0001). A
statistically significant, positive correlation was also
observed between IL-10 and GM-CSF (r= 0.151, P=
0.025), M-CSF (r= 0.138, P= 0.0417), CCL3 (r= 0.169,
P= 0.0125), FGF-basic (r= 0.146, P= 0.032), and TNF-α
(r= 0.197, P= 0.0035) that was present only in CMML
patients.
Clinical and genetic associations with the
inflammatory secretome
When comparing the CMML secretome with clinical
parameters, cytokine and chemokine secretion was asso-
ciated with a variety of clinically relevant features. For







Age, years 74 (29–91) 66 (60–80)
<65 32 (14.9%) 4 (11.4%)
≥65 176 (81.8%) 11 (31.4)
Data not available 7 (3.3%) 20 (57.1%)
Gender
Male 139 (64.7%) 9 (25.7%)
Female 76 (35.3%) 6 (17.1)









<10 g/dL 58 (27.0%)
≥10 g/dL 122 (56.7%)












Data not available 36 (16.7%)
Blasts in BM, %
<10% 148 (68.8%)
≥10% 25 (11.6%)




Data not available 43 (20.0%)
Presence of circulating immature cells
Yes 88 (40.9%)
No 74 (34.4%)
Data not available 53 (24.7%)
ASXL1 status
Mutated 49 (22.8%)
Wild type 121 (56.3%)
Data not available 45 (20.9%)
TET2 status
Mutation 87 (40.5%)
Wild type 62 (28.8%)
Data not available 66 (30.7%)
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example, patients who were classified as MPN-CMML by
the FAB had significantly elevated inflammatory cytokine
and chemokine secretion that included S100A8 (FC= 1.8,
P= 0.005), HGF (FC= 1.3, P= 0.004), MIF (FC= 1.5,
P= 0.006), and IL-1RA (FC= 1.3, P= 0.001). CCL3 was
found to be downregulated in MPN-CMML patients com-
pared to MDS-CMML patients (FC= 0.3, P= 0.012)
(Fig. 2a; Supplemental Table 7). Other relevant clinical
associations included IL-2RA (FC= 1.9, P < 0.001), which
statistically associated with higher risk CMML (Fig. 2b;
Supplemental Table 8) and IL-8 (FC= 2.1, P= 0.041) and
IL-2RA (FC= 0.045, P= 1.5), which statistically asso-
ciated with constitutional symptoms (Fig. 2c; Supplemental
Table 9). IL-8 (FC= 6.1, P= 0.04) was found to be pro-
foundly elevated in CMML patients classified in the
CMML-2 subcategory by 2016 WHO classification system
[1]. Interestingly, the association with constitutional
symptoms and IL-8 (FC= 2.1, P= 0.041) is consistent with
the clinical efficacy of ruxolitinib, an FDA approved JAK1/
2 inhibitor, that potently down-regulates IL-8 and improves
constitutional symptoms in patients with myelofibrosis and
CMML [22]. Patients with enlarged spleens by physical
exam were observed to have elevated CXCL9 levels
compared to those without enlarged spleen (FC= 1.6,
P= 0.042) (Fig. 2d; Supplemental Table 10). Finally,
CMML patients with anemia had elevated levels of IL-5
(FC= 1.2, P= 0.014) while those with thrombocytopenias
had elevated levels in IP-10/CXCL10 (FC= 1.9,
P= 0.005) and IL2-RA (FC= 1.5, P= 0.008) (Fig. 2e, f;
Supplemental Tables 11 and 12).
When comparing inflammatory cytokine secretion with
the presence or absence of commonly mutated genes, we
observed TET2 mutant patients had statistically decreased
levels of IL-6 (FC= 0.2, P= 0.005), PDGF-AA (FC= 0.4,
P < 0.001), and PDGF-DD (FC= 0.5, P= 0.007) (Fig. 3a,
Supplemental Table 13). Combining all mutated epigenetic
Fig. 2 Cytokine–phenotype
associations in CMML.
a Cytokine expression in
patients with MPN-CMML
compared to patients categorized
in MDS-CMML. Y-axis is
negative log(P-value). X-axis is
the calculated fold change from
the mean of the batch-adjusted
cytokine levels normalized to
healthy controls. b Cytokine
expression in patients with high-
risk CMML by Mayo Prognostic
Model compared to patients
categorized to low-risk CMML
by Mayo Prognostic Model.
c Cytokine expression in
CMML patients with
constitutional symptoms
compared to CMML patients
without constitutional
symptoms. d Cytokine
expression in CMML patients
with splenomegaly compared to
CMML patients without the
presence of splenomegaly.
e Cytokine expression in
CMML patients with
hemoglobin <10 g/dL compared
to CMML patients with
hemoglobin >10 g/dL.
f Cytokine expression in CMML
patients with platelet count
<100,000/μL compared to
CMML patients with platelet
count >100,000/μL
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regulator genes tested, significant increases in IL-1β (FC=
1.2, P= 0.029) secretion were observed (Fig. 3b, Supple-
mental Table 14). CMML patients with mutations in spli-
cing regulators had statistically elevated levels of IL-2
(FC= 1.7, P= 0.043) and CD44 (FC= 1.6, P= 0.041)
(Fig. 3c, Supplemental Table 15). However, other than
PDGF-AA, no cytokines were found to be significantly
different among patients with ASXL1 mutation compared to
those with wild-type ASXL1 (Fig. 3d, Supplemental
Table 16). CMML patients with signaling mutations,
alternatively, were found to have the greatest increases in
inflammatory cytokines to include IL-10 (FC= 3.8, P=
0.006), CCL2/MCP-1 (FC= 1.5, P= 0.033), CD44 (FC=
2.2, P= 0.002), IL-1RA (FC= 1.3, P= 0.027), IL-12
23p40 (FC= 6.6, P= 0.019), and CXCL7 (FC= 1.5,
P= 0.012) (Fig. 3e, Supplemental Table 17). CXCL7 has
been previously reported to be differentially methylated and
overexpressed in CMML patients resistant to decitabine
supporting its clinical relevance [36]. GM-CSF was
observed to be elevated in patients with signaling mutations,
with a fold change of 3.8 with P= 0.073, but it did not
reach statistical significance. Overall, distinct cytokine sig-
natures were associated with somatic mutations, but the
greatest number and increase were in those with signaling
mutations (Fig. 3e).
Unsupervised clustering analysis
Given these clinical and genetic associations with subsets of
cytokine/chemokine secretion, we next tested whether
unsupervised clustering of cytokines could identify clinical
subtypes of CMML using two different methods, RPMM
and Mclust. Using RPMM clustering, we found three dis-
tinct cluster groups when analyzed in 213 evaluable CMML
patients (Fig. 4a, Supplemental Tables 18 and 19). A total
of 69 patients (32%) were classified in cluster 1 driven by
Fig. 3 Cytokine genotype
associations in CMML.
a Cytokine expression in
patients in CMML patients with
the TET2 mutations compared to
CMML patients without TET2
mutations. Y-axis is negative log
(P-value). X-axis is the
calculated fold change from the
mean of the batch-adjusted
cytokine levels normalized to
healthy controls. b Cytokine
expression in patients in CMML
patients with the mutations in
epigenetic regular genes
compared to CMML patients
without those mutations.
c Cytokine expression in
patients in CMML patients with
mutations involving splicing
machinery compared to CMML
patients without those
mutations. d Cytokine
expression in patients in CMML
patients with ASXL1 mutations
compared to CMML patients
without ASXL1 mutations.
e Cytokine expression in
patients in CMML patients with
mutations involving signal
transduction and tyrosine kinase
pathway compared to CMML
patients without those mutations
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statistically significant increases in M-CSF (Supplemental
Table 15). A total of 42 patients (20%) were classified in
cluster 2 driven by statistically significant increases in 17
cytokines including IL-6, IL-8, and IL-12p70 cytokines
(Supplemental Table 20). A total of 102 patients (48%)
were classified in cluster 3 driven by statistically significant
increases in IL-2RA (Fig. 4, Supplemental Table 18). We
observed that a larger proportion of CMML patients
with anemia with hemoglobin <10 (32 of 58 patients,
55.2%, P= 0.058) and thrombocytopenia with platelet
count <100,000 (55 of 88 patients, 62.5%, P < 0.001) were
categorized into cluster 3. Additionally, we observed that
patients were significantly more likely to be lower risk by
the Mayo score (P= 0.003) [17] and the Global MD
Anderson score (P= 0.08) [10, 37] when assigned to cluster
2. Last, the presence of immature myeloid cells, an adverse
clinical factor in CMML, was associated with Clusters 1
and 3 (P= 0.012). When comparing OS between our three
distinct cluster groups, no statistical difference was
observed (Supplemental Fig. 3). All tested variables and
their statistical significance are presented in Supplemental
Tables 20 and 21.
Impact of cytokines on survival
Using log-rank tests with all cytokines (measured as binary
variable high/low), we identified M-CSF (P= 0.012, HR
0.74, 95% CI 0.58–0.94), IL-13 (P= 0.035, HR 5.59, 95%
CI 1.34–23.3), and IL-10 (P= 0.037, HR 0.8, 95% CI
0.65–0.98) to be associated with OS in CMML. Confirming
this, we observed that CMML patients with decreased IL-10
expression (median IL-10= 0.895939) had an inferior OS
when compared to CMML patients with elevated expres-
sion of IL-10 by Kaplan–Meier analysis (median OS of
46.98 vs 79.84 months, P= 0.0166) (Supplemental Figs. 4
and 5A). Despite small numbers of patients in subgroup
analysis, investigating IL-10 expression across Mayo
prognostic risk groups in CMML patients consistently
Fig. 4 Unsupervised cluster analysis identifies three groups driven by
cytokine signatures. Heatmap of batch-adjusted cytokine levels with
cluster assignments denoted on the legend based on either RPMM (3
clusters) or Gaussian mixed-model clustering (4 clusters) when cyto-
kine expression was analyzed in CMML patients (N= 213)
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demonstrated that those with elevated IL-10 secretion had a
favorable OS [17] (Supplemental Fig. 5B–I).
To evaluate whether cytokines can improve our current
prognostic systems in CMML, we conducted log-rank tests
on clinical and genetic variables, and found significant risk
factors for survival that included anemia, absolute mono-
cyte count, elevated WBC count, the presence of ASXL1
mutation, and FAB-MPN status (Supplemental Table 22).
To create a final model that could predict OS and leukemia-
free survival, we used a backward selection to eliminate
non-significant variables when considering the above clin-
ical and genetic variables, including age, hemoglobin, pla-
telet count, monocyte count, bone marrow blast percentage,
presence of circulating immature cells, ASXL1, FAB-MPN,
and CMML-specific cytogenetic risk score. (Tables 2 and 3,
Supplemental Tables 22 and 23). When considering this,
IL-10, hemoglobin <10 g/dL, ASXL1 mutation status, and
FAB-MPN status remained statistically significant
(Table 2). Because the vast majority of these clinical and
genetic variables were previously identified by the Mayo
Molecular Model [17], we tested the additive prognostic
power of IL-10 expression (including ASXL1 mutation
status) and found that IL-10 statistically improved the Mayo
CMML prognostic score model [17] (C-Index of 0.6736317
(model without IL-10) vs 0.7367075 (model with IL-10),
P= 0.01871) in our patient cohort (Supplemental
Table 22).
Impact of IL-10 and IL-8 on colony formation in
primary CMML patient samples
CFAs were performed in duplicate from cryopreserved bone
marrow mononuclear cells of seven CMML patients. Four
of the patients were found to have elevated IL-10 expres-
sion (above median IL-10= 0.895939) using our custom
luminex assay and three of the patients were found to have
low IL-10 expression. We compared colony output between
IL-10 treated patient sample, IL-8 treated patient sample,
and untreated patient sample. We observed lower colony
formation output in our CMML patients with decreased IL-
10 expression (P= 0.054) (Supplementary Figure 6A). In
CMML patients with elevated IL-10 expression, again we
observed decreased colony formation potential compared to
our untreated sample which was statistically significant
(P= 0.025) (Supplementary Figure 6B). When all seven
samples in duplicated treated with IL-10 was compared to
the untreated samples, we persistently found decreased
colony formation in IL-10-treated samples (P= 0.0007)
(Supplementary Figure 5C). We, however, observed
increased colony formation in IL-8-treated samples com-
pared to our untreated samples which was statistically sig-
nificant (P= 0.017) (Supplementary Figure 6D–F). RNA
gene expression analysis comparing untreated cultured
primary CMML bone marrow mononuclear cells to those
treated with IL-10 found upregulation in cell cycle apoptotic
pathways using Nanostring PanCancer Pathway (Supple-
mentary Figure 6G, H, I).
Discussion
CMML is characterized by clinical heterogeneity that can-
not be molecularly explained by known recurrent genetic
mutations alone. Previous studies have demonstrated that
elevated inflammatory cytokines in MPNs, such as PMF,
Table 2 Significant variables
associated with overall survival
(OS)








IL-10 High 84 0.48 (0.26–0.89) 0.019 0.019 0.017
Low 90 – –
Mayo CMML
prognostic model
High 43 4.20 (1.71–10.31) 0.002 0.002 <0.001
Low 66 – –
ASXL1 Positive 44 3.07 (1.52–6.21) 0.002 0.002 0.001
Negative 97 – –
Table 3 Overall survival according to the defined risk categories in the














Low 39 (22.4) 68.0 23.1
Intermediate 122 (70.1) 56.0 8.2
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correlate with clinical phenotypes and are associated with
OS [24]. However, cytokine expression has never been
evaluated in patients with CMML. Given the clinical
responses to ruxolitinib, we reasoned that the inflammatory
secretome may play an important role in the pathogenesis of
CMML. To explore this, we profiled 45 inflammatory
cytokines and chemokines in CMML patients, demonstrat-
ing that proinflammatory cytokines were heterogeneously
expressed in CMML patients with 23 of 45 cytokines that
were significantly discordant to matched healthy controls.
Of interest, approximately 50% of these cytokine/chemo-
kines were increased in CMML and 50% were decreased.
Within clinical CMML subgroups, this heterogeneity
appeared to coincide with clinically relevant phenotypes. As
an illustration, proliferative CMML, which diversely com-
bine leukocytosis, splenomegaly, and constitutional symp-
toms, was typically associated with a strong inflammatory
cytokine profile. Cytokine heterogeneity also aligned with
mutational signatures. For example, the largest number of
inflammatory cytokines were, not surprisingly, associated
with those patients that harbored a cytokine signaling
mutation. However other genetic associations identified
were unexpected. For example, it has been previously
reported that TET2 function is associated with suppression
of IL-6 and increased production of IL-6 in TET2-deficient
mice; however, our results found the opposite effect
[38, 39]. In our cohort, we observed decreased IL-6
expression in CMML patients with mutated TET2, sug-
gesting that there are complex molecular interactions in
human, polygenetic disease not predicted by single gene
models (Fig. 3a).
Using unbiased cluster analysis, we were able to further
validate the capacity of cytokine secretion to account for
CMML clinical diversity. Surprisingly, while the greatest
number of elevated individual cytokines was found in those
CMML patients with proliferative symptomatology, cluster
analysis was able to identify associations with higher risk
disease and cytopenias. These are important clinical vari-
ables, albeit not associated with proliferative disease, sug-
gesting that complex networks of cytokines may also
govern ‘dysplastic’ symptomatology. In support of this,
cytokine association studies demonstrated that CMML
patients have, in addition to discordance in individual
cytokine secretion, loss of normal cytokine associations.
Although the present study represents the first inter-
rogation of inflammatory cytokines/chemokines in CMML,
circulating cytokine levels have been previously evaluated
in PMF and other myeloid diseases [1, 24]. When com-
paring abnormal cytokine secretion between CMML and
PMF, for example, several cytokines in CMML patients that
were elevated compared to healthy controls were also
increased in PMF patients, including IL-1RA, Il-2RA, IL-6,
IL-8, TNF-α, HGF, IP-10, MCP-1, and VEGF [24]. Further,
cytokine–phenotype associations discovered in our cohort
were also seen in PMF, validating our findings. Specifically,
statistically increased IL-8 expression in patients with
constitutional symptoms was observed in our cohort and in
PMF (Fig. 2c, Supplemental Table 6) [24]. However, not
every cytokine association in CMML was similar to that in
PMF. IFN-γ was found to be decreased in PMF, but in our
cohort, IFN-γ was elevated in CMML patients compared to
healthy controls, though it did not reach statistical sig-
nificance [24]. Further, 50% of cytokines differentially
secreted were decreased in CMML, a number far greater
than in PMF. Of these cytokines, RANTES/CCL5 was
among the most decreased cytokines in CMML, with
similar findings previously reported in MDS and aplastic
anemia, providing cytokine-level support for the phenotypic
overlap between bone marrow failure and myeloprolifera-
tion in CMML [40].
Prognostic risk models are valuable tools for assessing
individual disease risk and clinical decision-making. In
CMML, these risks models have modest predictive capacity
even after adding prognostically informative genetic muta-
tions. We identified IL-10 as an independent prognostic
factor for OS in CMML, consistent with findings in other
malignancies [41, 42]. This cytokine has been observed to
suppress cytokine secretion and inhibit the induction of
proinflammatory cytokines such as IL-1β, TNF-α, GM-
CSF, and IFN-γ [43]. Further, CMML patients with
downregulated IL-10 expression were identified to have
poor OS when compared to CMML patients with elevated
expression of IL-10 (P= 0.0166). Importantly, the addition
of IL-10 statistically improved the predictive power of the
Mayo Molecular Model [17] within our cohort. Although
the magnitude of improvement was small, these data pro-
vide the foundational evidence supporting the notion that
inflammatory cytokines represent a tractable, clinically
relevant molecular characteristic of CMML. In fact, a
sequential analysis of eight CMML patients treated with
13.75 mean cycles of 5-azacitidine demonstrated that 50%
(16 of 32 tested) of cytokines tested were statistically aug-
mented by therapy suggestive that inflammatory cytokines
may have therapeutic relevance (Supplemental Figure 7).
IL-10 is a multifunctional cytokine produced by several
cell types including monocytes and has been described to
have both immunosuppressive and proinflammatory prop-
erties [43–45]. IL-10 has been implicated in the pathogen-
esis of multiple tumor types including CMML, and its
potential to suppress cytokine expression has made it of
particular interest as a possible therapeutic target [46–49].
Geissler et al. [50] observed that IL-10 could inhibit the
growth of CMML primary cells in a dose-dependent man-
ner in vitro potentially via the suppression of endogenous
GM-CSF. The group observed that treatment of exogenous
GM-CSF was able to reverse IL-10 growth inhibition of
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CMML primary cells, and observed that GM-CSF mRNA
levels and protein levels were decreased after treatment with
IL-10 [50]. In our cohort, we observed that CMML patients
with high IL-10 expression had a favorable OS perhaps
mediated by IL-10 growth suppression of CMML leukemia
cells. In support of this notion, a small study of five CMML
patients treated with recombinant human IL-10 observed
some clinical efficacy with improvement in one of three
patients with confirmed skin infiltration by CMML sug-
gesting that IL-10 is a potential therapeutic target [51]. Our
own experiment confirmed decreased colony formation in
primary CMML patient samples treated with IL-10 com-
pared to untreated samples and IL-8-treated samples (Sup-
plementary Figure 6).
Our study comprehensively evaluated cytokine expres-
sion in CMML patients, which has not been evaluated in the
literature to understand the pathophysiology as well as
evaluate the potential for new therapeutic targets. The
annotation of inflammatory cytokine/chemokines in this
study also raises several important questions. For example,
what is the individual contribution of the stroma and
the leukemic cells to the overall cytokine milieu? Addi-
tionally, can inhibition of cytokines critical to the sympto-
matology of CMML such as IL-8 be selectively targeted in
CMML? Based on the findings from this study, further
investigation is warranted into the inflammatory state of
CMML, its therapeutic relevance, and its use to improve
our current prognostic models. Last, our data demonstrate
that IL-10 has the potential to improve existing clinical
and genetic prognostic model and serve as a therapeutic
target in CMML.
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